Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma Qunling Zhang,1,2 Junning Cao,1,2 Kai Xue,1,2 Xiaojian Liu,1,2 Dongmei Ji,1,2 Ye Guo,1,2 Xiaonan Hong1,2
II study Rui-Hua Xu Jin Li 0 1 Yuxian Bai Jianming Xu Tianshu Liu Lin Shen Liwei Wang Hongming Pan Junning Cao 0 Dongsheng Zhang Songhua Fan Ye Hua Weiguo Su 0 Department of Medical Oncology, Fudan
Background AST1306 is an orally active irreversible small molecule inhibitor of EGFR (erbB1), HER2 (erbB2) and HER4 (erbB4) signaling. This is a phase I, open-label, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor effects of oral AST1306. In addition the effects of food on PK was tested. Methods A modified Fibonacci...
Jin Kim 1 Hyun Ae Jung 1 Shih-Sung Chuang Huangming Hong 0 Cheng-Cheng Guo 0 Junning Cao Xiao-Nan Hong Ritsuro Suzuki Hye Jin Kang Jong Ho Won Wee-Joo Chng Yok-Lam Kwong Cheolwon Suh Yu-Qin Song Jun Zhu